Why HeartFlow Stock Rocketed 14% Higher Today

Core Insights - HeartFlow's stock experienced a 14% increase following FDA approval of its HeartFlow Plaque Analysis algorithm, despite the S&P 500 closing slightly negative [1][2] Product Development - The FDA granted approval for HeartFlow's HeartFlow Plaque Analysis, which is now available for sale [2][7] - The new version of the HeartFlow Plaque Analysis shows a 21% improvement in plaque detection compared to the first-generation product, utilizing data from approximately 273,000 patients [4] Market Impact - Cigna, a major health insurer, has updated its policies to cover the use of HeartFlow Plaque Analysis, effective October 1 [5]